Literature DB >> 11114637

Randomized trial of parathyroidectomy in mild asymptomatic primary hyperparathyroidism: patient description and effects on the SF-36 health survey.

G B Talpos1, H G Bone, M Kleerekoper, E R Phillips, M Alam, M Honasoge, G W Divine, D S Rao.   

Abstract

BACKGROUND: The treatment of patients with asymptomatic primary hyperparathyroidism remains controversial despite a National Institutes of Health consensus statement. This statement also recommended a randomized clinical trial because none exists to address this issue.
METHODS: Informed consent was obtained from 53 asymptomatic patients with confirmed asymptomatic primary hyperparathyroidism who participated in this randomized trial of parathyroidectomy versus observation. Patients completed the SF-36 Health Survey, an instrument that measures wellness, every 6 months for 2 years. Average annual changes were compared.
RESULTS: Fifty-three patients (42 female, 11 male) with asymptomatic, mild (serum calcium level, 10.1-11.5 mg/dL) asymptomatic primary hyperparathyroidism who agreed to participate were randomized into either a surgical group or an observation group. The mean calcium level was 10.31 mg/dL. The only demographic difference between groups was age, with the operative group being older (66.7 vs 62.6 years; P <.03). The scores on 2 of the 9 domains of the SF-36 were significantly different (P <.007 and <.012, respectively); both favored the operative group.
CONCLUSIONS: Improved function is seen after parathyroidectomy when compared with patients who did not undergo operation. This study supports surgical management of mild primary hyperparathyroidism at the time of diagnosis because many patients have reversible nonclassic symptoms of the disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11114637     DOI: 10.1067/msy.2000.110844

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  35 in total

Review 1.  Parathyroidectomy for asymptomatic primary hyperparathyroidism (PHPT): is it worth the risk?

Authors:  J Rastad
Journal:  J Endocrinol Invest       Date:  2001-01       Impact factor: 4.256

2.  Surgery for primary hyperparathyroidism.

Authors:  Henrik Ancher Sørensen
Journal:  BMJ       Date:  2002-10-12

3.  Persistent symptomatic improvement in the majority of patients undergoing parathyroidectomy for primary hyperparathyroidism.

Authors:  Preethi Gopinath; Gregory P Sadler; Radu Mihai
Journal:  Langenbecks Arch Surg       Date:  2010-07-25       Impact factor: 3.445

4.  Instilling a culture of evidence-based surgery in Canada.

Authors:  Robin S McLeod
Journal:  World J Surg       Date:  2007-08       Impact factor: 3.352

Review 5.  Mild primary hyperparathyroidism: a literature review.

Authors:  Megan K Applewhite; David F Schneider
Journal:  Oncologist       Date:  2014-07-25

6.  Cinacalcet normalizes serum calcium in a double-blind randomized, placebo-controlled study in patients with primary hyperparathyroidism with contraindications to surgery.

Authors:  Aliya Khan; John Bilezikian; Henry Bone; Andrey Gurevich; Peter Lakatos; Waldemar Misiorowski; Liudmila Rozhinskaya; Marie-Louise Trotman; Miklós Tóth
Journal:  Eur J Endocrinol       Date:  2015-01-30       Impact factor: 6.664

Review 7.  Primary hyperparathyroidism.

Authors:  John P Bilezikian; Natalie E Cusano; Aliya A Khan; Jian-Min Liu; Claudio Marcocci; Francisco Bandeira
Journal:  Nat Rev Dis Primers       Date:  2016-05-19       Impact factor: 52.329

Review 8.  What symptom improvement can be expected after operation for primary hyperparathyroidism?

Authors:  Nadine R Caron; Janice L Pasieka
Journal:  World J Surg       Date:  2009-11       Impact factor: 3.352

9.  Timing of symptom improvement after parathyroidectomy for primary hyperparathyroidism.

Authors:  Sara E Murray; Priya R Pathak; David S Pontes; David F Schneider; Sarah C Schaefer; Herbert Chen; Rebecca S Sippel
Journal:  Surgery       Date:  2013-10-04       Impact factor: 3.982

10.  Clinical presentation and management of patients with primary hyperparathyroidism of the Swiss Primary Hyperparathyroidism Cohort: a focus on neuro-behavioral and cognitive symptoms.

Authors:  A Trombetti; E R Christ; C Henzen; G Gold; M Brändle; F R Herrmann; C Torriani; F Triponez; M Kraenzlin; R Rizzoli; C Meier
Journal:  J Endocrinol Invest       Date:  2016-01-07       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.